(Q43275812)

18 November 2017

Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity (English)

1 reference

18 November 2017

1 reference

Akito Natsume

1

1 reference

18 November 2017

Yukiko Shimizu-Yokoyama

2

1 reference

18 November 2017

Mitsuo Satoh

3

1 reference

18 November 2017

Kenya Shitara

4

1 reference

18 November 2017

Rinpei Niwa

5

1 reference

18 November 2017

25 August 2009

1 reference

18 November 2017

1 reference

18 November 2017

100

1 reference

18 November 2017

12

1 reference

18 November 2017

2411-2418

1 reference

Complement activation determines the therapeutic activity of rituximab in vivo.

18 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01327.X

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01327.X

Engineered antibodies with increased activity to recruit complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01327.X

Modulation of the effector functions of a human IgG1 through engineering of its hinge region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01327.X

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1074/JBC.M202069200

Identifiers

DOI

10.1111/J.1349-7006.2009.01327.X

1 reference

18 November 2017

1 reference